Last reviewed · How we verify
NCT05257746: PERIFUNC
Perioperative and Postoperative Evaluation of Rectal and Urogenital Function in Patients Undergoing Rectal Resection
trial testing Rectal resection in Rectal Surgery in 500 participants. Currently enrolling.
30 June 2030
Quick facts
| Lead sponsor | Technische Universität Dresden |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 3 March 2021 |
| Primary completion | 30 June 2030 |
| Estimated completion | 30 June 2030 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Rectal resection
Conditions studied
- Rectal Surgery — all drugs for Rectal Surgery →
Sponsor
Technische Universität Dresden — full company profile →
Who can join
18 and older, any sex, with Rectal Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the systematic analysis of the development of perioperative rectal and urogenital function in patients undergoing rectal resection with total mesorectal excision and the identification of risk factors for urogenital and sphincter function loss after this procedure. Knowledge of the corresponding risk factors could enable the identification of patient cohorts that could benefit from an intensified or altered postoperative treatment path. The results of this study could thus significantly influence the clinical management of patients with rectal cancer and improve the functional outcome in the long term.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05257746
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rectal resection
Trials testing the same drug.
- NCT03899870 — Factors Predicting Recurrence in Rectal Cancer After Surgery · completed
Other Technische Universität Dresden trials
Trials by the same sponsor.
- NCT07150598 — Immune-Marker Platform for Patients With Advanced Lung Cancer · not yet recruiting
- NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
- NCT06701487 — Role of Pavlovian Mechanisms for Control Over Substance Use · recruiting
- NCT03865277 — Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging · Phase 2 · not yet recruiting
- NCT06293170 — Automated Screening for Clinically Ascertained Loss of Cerebral Functions · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05257746 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Technische Universität Dresden
- Last refreshed: 13 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05257746.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing